Pharmacoeconomic evaluations in the treatment of actinic keratoses
Actinic keratoses (AKs) develop as a consequence of chronic ultraviolet (UV) exposure and exist on a continuum with squamous cell carcinoma (SCC). As one of the most common conditions treated by dermatologists, AK places a significant burden on patients and the healthcare system. A range of treatmen...
Gespeichert in:
| Veröffentlicht in: | International journal of immunopathology and pharmacology 2017-06, Vol.30 (2), p.178-181 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 181 |
|---|---|
| container_issue | 2 |
| container_start_page | 178 |
| container_title | International journal of immunopathology and pharmacology |
| container_volume | 30 |
| creator | Tolley, Keith Argenziano, Giuseppe Calzavara-Pinton, Pier Giacomo Larsson, Thomas Ryttig, Lasse |
| description | Actinic keratoses (AKs) develop as a consequence of chronic ultraviolet (UV) exposure and exist on a continuum with squamous cell carcinoma (SCC). As one of the most common conditions treated by dermatologists, AK places a significant burden on patients and the healthcare system. A range of treatments are used, including topical treatments that target the visible and subclinical lesions. The goal of such therapies is to achieve complete clearance of AKs and eliminate the risk of progression to SCC. Robust meta-analyses of trial data can provide valuable information for the optimal management of AK and cost-effectiveness evaluations of topical treatments, such as ingenol mebutate gel and diclofenac. These outcomes can facilitate prescribing physicians’ decisions and shape therapeutic guidelines. Peer-reviewed meta-analysis publications and treatment guidelines favoured ingenol mebutate efficacy over diclofenac and the relative cost-effectiveness of ingenol mebutate. We discuss and critique recent evidence, from a cost-effectiveness analysis of 3% diclofenac sodium and ingenol mebutate in the treatment of AK in Italy, which has challenged this view. |
| doi_str_mv | 10.1177/0394632017697719 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5806796</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0394632017697719</sage_id><sourcerecordid>1906139048</sourcerecordid><originalsourceid>FETCH-LOGICAL-c488t-e546bca1c508eea59c5c9b1d4b152bcf59b20d2616adabb6119d4f85ed2749093</originalsourceid><addsrcrecordid>eNp1kUtr3TAQhUVpaUKafVbBkE03bmdkPTeFJLRNIdAu2rWQ5XGuU9tKJDmQfx-Hm1cDXWlA35w5h8PYAcInRK0_Q2OFajigVlZrtG_YLgdpat0Y8fbFvMP2c74EAIRGSIPv2Q430oDRuMtOfm18mnyIFOIcpyFUdOPHxZchzrka5qpsqCqJfJloLlXsKx_KMK_cX0q-xEz5A3vX-zHT_sO7x_58-_r79Kw-__n9x-nxeR2EMaUmKVQbPAYJhshLG2SwLXaiRcnb0Evbcui4QuU737YK0XaiN5I6roUF2-yxL1vdq6WdqAurn-RHd5WGyadbF_3g_v2Zh427iDduzaq0VavAxweBFK8XysVNQw40jn6muGSHFhQ2FoRZ0aNX6GVc0rzGc1xwKZUGfe8ItlRIMedE_ZMZBHffkXvd0bpy-DLE08JjIytQb4HsL-j56n8F7wAZ25nJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425567079</pqid></control><display><type>article</type><title>Pharmacoeconomic evaluations in the treatment of actinic keratoses</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Sage Journals GOLD Open Access 2024</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Tolley, Keith ; Argenziano, Giuseppe ; Calzavara-Pinton, Pier Giacomo ; Larsson, Thomas ; Ryttig, Lasse</creator><creatorcontrib>Tolley, Keith ; Argenziano, Giuseppe ; Calzavara-Pinton, Pier Giacomo ; Larsson, Thomas ; Ryttig, Lasse</creatorcontrib><description>Actinic keratoses (AKs) develop as a consequence of chronic ultraviolet (UV) exposure and exist on a continuum with squamous cell carcinoma (SCC). As one of the most common conditions treated by dermatologists, AK places a significant burden on patients and the healthcare system. A range of treatments are used, including topical treatments that target the visible and subclinical lesions. The goal of such therapies is to achieve complete clearance of AKs and eliminate the risk of progression to SCC. Robust meta-analyses of trial data can provide valuable information for the optimal management of AK and cost-effectiveness evaluations of topical treatments, such as ingenol mebutate gel and diclofenac. These outcomes can facilitate prescribing physicians’ decisions and shape therapeutic guidelines. Peer-reviewed meta-analysis publications and treatment guidelines favoured ingenol mebutate efficacy over diclofenac and the relative cost-effectiveness of ingenol mebutate. We discuss and critique recent evidence, from a cost-effectiveness analysis of 3% diclofenac sodium and ingenol mebutate in the treatment of AK in Italy, which has challenged this view.</description><identifier>ISSN: 2058-7384</identifier><identifier>ISSN: 0394-6320</identifier><identifier>EISSN: 2058-7384</identifier><identifier>DOI: 10.1177/0394632017697719</identifier><identifier>PMID: 28580871</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Carcinoma, Squamous Cell ; Cost analysis ; Diclofenac ; Diterpenes ; Economics ; Economics, Pharmaceutical ; Humans ; Italy ; Keratosis, Actinic ; Letters to the Editor ; Nonsteroidal anti-inflammatory drugs ; Pharmacology ; Squamous cell carcinoma ; Ultraviolet radiation</subject><ispartof>International journal of immunopathology and pharmacology, 2017-06, Vol.30 (2), p.178-181</ispartof><rights>The Author(s) 2017</rights><rights>The Author(s) 2017. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2017 2017 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c488t-e546bca1c508eea59c5c9b1d4b152bcf59b20d2616adabb6119d4f85ed2749093</citedby><cites>FETCH-LOGICAL-c488t-e546bca1c508eea59c5c9b1d4b152bcf59b20d2616adabb6119d4f85ed2749093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806796/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806796/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,21966,27853,27924,27925,44945,45333,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28580871$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tolley, Keith</creatorcontrib><creatorcontrib>Argenziano, Giuseppe</creatorcontrib><creatorcontrib>Calzavara-Pinton, Pier Giacomo</creatorcontrib><creatorcontrib>Larsson, Thomas</creatorcontrib><creatorcontrib>Ryttig, Lasse</creatorcontrib><title>Pharmacoeconomic evaluations in the treatment of actinic keratoses</title><title>International journal of immunopathology and pharmacology</title><addtitle>Int J Immunopathol Pharmacol</addtitle><description>Actinic keratoses (AKs) develop as a consequence of chronic ultraviolet (UV) exposure and exist on a continuum with squamous cell carcinoma (SCC). As one of the most common conditions treated by dermatologists, AK places a significant burden on patients and the healthcare system. A range of treatments are used, including topical treatments that target the visible and subclinical lesions. The goal of such therapies is to achieve complete clearance of AKs and eliminate the risk of progression to SCC. Robust meta-analyses of trial data can provide valuable information for the optimal management of AK and cost-effectiveness evaluations of topical treatments, such as ingenol mebutate gel and diclofenac. These outcomes can facilitate prescribing physicians’ decisions and shape therapeutic guidelines. Peer-reviewed meta-analysis publications and treatment guidelines favoured ingenol mebutate efficacy over diclofenac and the relative cost-effectiveness of ingenol mebutate. We discuss and critique recent evidence, from a cost-effectiveness analysis of 3% diclofenac sodium and ingenol mebutate in the treatment of AK in Italy, which has challenged this view.</description><subject>Carcinoma, Squamous Cell</subject><subject>Cost analysis</subject><subject>Diclofenac</subject><subject>Diterpenes</subject><subject>Economics</subject><subject>Economics, Pharmaceutical</subject><subject>Humans</subject><subject>Italy</subject><subject>Keratosis, Actinic</subject><subject>Letters to the Editor</subject><subject>Nonsteroidal anti-inflammatory drugs</subject><subject>Pharmacology</subject><subject>Squamous cell carcinoma</subject><subject>Ultraviolet radiation</subject><issn>2058-7384</issn><issn>0394-6320</issn><issn>2058-7384</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1kUtr3TAQhUVpaUKafVbBkE03bmdkPTeFJLRNIdAu2rWQ5XGuU9tKJDmQfx-Hm1cDXWlA35w5h8PYAcInRK0_Q2OFajigVlZrtG_YLgdpat0Y8fbFvMP2c74EAIRGSIPv2Q430oDRuMtOfm18mnyIFOIcpyFUdOPHxZchzrka5qpsqCqJfJloLlXsKx_KMK_cX0q-xEz5A3vX-zHT_sO7x_58-_r79Kw-__n9x-nxeR2EMaUmKVQbPAYJhshLG2SwLXaiRcnb0Evbcui4QuU737YK0XaiN5I6roUF2-yxL1vdq6WdqAurn-RHd5WGyadbF_3g_v2Zh427iDduzaq0VavAxweBFK8XysVNQw40jn6muGSHFhQ2FoRZ0aNX6GVc0rzGc1xwKZUGfe8ItlRIMedE_ZMZBHffkXvd0bpy-DLE08JjIytQb4HsL-j56n8F7wAZ25nJ</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Tolley, Keith</creator><creator>Argenziano, Giuseppe</creator><creator>Calzavara-Pinton, Pier Giacomo</creator><creator>Larsson, Thomas</creator><creator>Ryttig, Lasse</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170601</creationdate><title>Pharmacoeconomic evaluations in the treatment of actinic keratoses</title><author>Tolley, Keith ; Argenziano, Giuseppe ; Calzavara-Pinton, Pier Giacomo ; Larsson, Thomas ; Ryttig, Lasse</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c488t-e546bca1c508eea59c5c9b1d4b152bcf59b20d2616adabb6119d4f85ed2749093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Carcinoma, Squamous Cell</topic><topic>Cost analysis</topic><topic>Diclofenac</topic><topic>Diterpenes</topic><topic>Economics</topic><topic>Economics, Pharmaceutical</topic><topic>Humans</topic><topic>Italy</topic><topic>Keratosis, Actinic</topic><topic>Letters to the Editor</topic><topic>Nonsteroidal anti-inflammatory drugs</topic><topic>Pharmacology</topic><topic>Squamous cell carcinoma</topic><topic>Ultraviolet radiation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tolley, Keith</creatorcontrib><creatorcontrib>Argenziano, Giuseppe</creatorcontrib><creatorcontrib>Calzavara-Pinton, Pier Giacomo</creatorcontrib><creatorcontrib>Larsson, Thomas</creatorcontrib><creatorcontrib>Ryttig, Lasse</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of immunopathology and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tolley, Keith</au><au>Argenziano, Giuseppe</au><au>Calzavara-Pinton, Pier Giacomo</au><au>Larsson, Thomas</au><au>Ryttig, Lasse</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacoeconomic evaluations in the treatment of actinic keratoses</atitle><jtitle>International journal of immunopathology and pharmacology</jtitle><addtitle>Int J Immunopathol Pharmacol</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>30</volume><issue>2</issue><spage>178</spage><epage>181</epage><pages>178-181</pages><issn>2058-7384</issn><issn>0394-6320</issn><eissn>2058-7384</eissn><abstract>Actinic keratoses (AKs) develop as a consequence of chronic ultraviolet (UV) exposure and exist on a continuum with squamous cell carcinoma (SCC). As one of the most common conditions treated by dermatologists, AK places a significant burden on patients and the healthcare system. A range of treatments are used, including topical treatments that target the visible and subclinical lesions. The goal of such therapies is to achieve complete clearance of AKs and eliminate the risk of progression to SCC. Robust meta-analyses of trial data can provide valuable information for the optimal management of AK and cost-effectiveness evaluations of topical treatments, such as ingenol mebutate gel and diclofenac. These outcomes can facilitate prescribing physicians’ decisions and shape therapeutic guidelines. Peer-reviewed meta-analysis publications and treatment guidelines favoured ingenol mebutate efficacy over diclofenac and the relative cost-effectiveness of ingenol mebutate. We discuss and critique recent evidence, from a cost-effectiveness analysis of 3% diclofenac sodium and ingenol mebutate in the treatment of AK in Italy, which has challenged this view.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>28580871</pmid><doi>10.1177/0394632017697719</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2058-7384 |
| ispartof | International journal of immunopathology and pharmacology, 2017-06, Vol.30 (2), p.178-181 |
| issn | 2058-7384 0394-6320 2058-7384 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5806796 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Sage Journals GOLD Open Access 2024; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Carcinoma, Squamous Cell Cost analysis Diclofenac Diterpenes Economics Economics, Pharmaceutical Humans Italy Keratosis, Actinic Letters to the Editor Nonsteroidal anti-inflammatory drugs Pharmacology Squamous cell carcinoma Ultraviolet radiation |
| title | Pharmacoeconomic evaluations in the treatment of actinic keratoses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T23%3A33%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacoeconomic%20evaluations%20in%20the%20treatment%20of%20actinic%20keratoses&rft.jtitle=International%20journal%20of%20immunopathology%20and%20pharmacology&rft.au=Tolley,%20Keith&rft.date=2017-06-01&rft.volume=30&rft.issue=2&rft.spage=178&rft.epage=181&rft.pages=178-181&rft.issn=2058-7384&rft.eissn=2058-7384&rft_id=info:doi/10.1177/0394632017697719&rft_dat=%3Cproquest_pubme%3E1906139048%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2425567079&rft_id=info:pmid/28580871&rft_sage_id=10.1177_0394632017697719&rfr_iscdi=true |